• Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF

• Patent Issuance Will Provide Additional IP Protection for MANF Protein Therapy and Cell Therapy

SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.

Amarantus BioScience Holdings, Inc. (AMBS-OTC) provided investors with an important update today regarding the company's plans to initiate a Phase 2b clinical study of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia, or PD-LID.